Protalix BioTherapeutics, Inc. (PLX) has a negative trailing P/E of -26.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 11.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -3.78%, forward earnings yield 9.11%.
Criteria proven by this page:
Overall SharesGrow Score: 53/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -15.4 | 0.10 | -45.31 | 49.05 | - |
| 2017 | -1.0 | 0.00 | -2.77 | 4.11 | - |
| 2018 | -1.7 | 0.02 | -0.87 | 1.34 | - |
| 2019 | -2.7 | 0.08 | -0.69 | 0.89 | - |
| 2020 | -16.2 | 0.20 | -3.91 | 1.68 | - |
| 2021 | -1.3 | -0.01 | -6.08 | 0.96 | - |
| 2022 | -4.4 | 0.09 | -6.24 | 1.39 | - |
| 2023 | 14.5 | -0.10 | 3.58 | 1.83 | - |
| 2024 | 46.5 | -0.70 | 3.16 | 2.55 | - |
| 2025 | -21.4 | 0.07 | 2.93 | 2.68 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.29 | $9.2M | $-29.37M | -319.2% |
| 2017 | $-6.50 | $21.08M | $-83.44M | -395.9% |
| 2018 | $-1.80 | $34.24M | $-26.46M | -77.3% |
| 2019 | $-1.23 | $54.69M | $-18.28M | -33.4% |
| 2020 | $-0.22 | $62.9M | $-6.52M | -10.4% |
| 2021 | $-0.62 | $38.35M | $-27.58M | -71.9% |
| 2022 | $-0.31 | $47.64M | $-14.93M | -31.3% |
| 2023 | $0.10 | $65.49M | $8.31M | 12.7% |
| 2024 | $0.04 | $53.4M | $2.93M | 5.5% |
| 2025 | $-0.08 | $52.74M | $-6.6M | -12.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.22 | $0.17 – $0.25 | $79.05M | $78.42M – $79.66M | 2 |
| 2027 | $0.07 | $0.07 – $0.07 | $69.04M | $61.98M – $76.1M | 2 |
